Assessments of COVID-19's impact on cardiovascular functional parameters in patients affected with myocardial infarction
Researcher Bulletin of Medical Sciences,
Vol. 30 No. 1 (2025),
20 Khordad 2026
,
Page e12
Abstract
Objective: Corona virus can severely affect the performance and functional parameters of the heart, causing damage to the myocardium and reducing the ejection fraction in patients with this disease. The present study was conducted with the aim of investigating the changes in cardiovascular parameters such as cardiac ejection fraction, blood pressure and heart rate after myocardial infarction in patients with covid-19 and comparing it with non-covid-19 patients.
Materials and Methods: In this case-control study and based on purpose-based sampling, among all the patients' files in Imam Musa bin Jafar (AS) hospital in Qochan city, who were hospitalized with a diagnosis of heart attack and since the beginning of the outbreak of the Covid-19 disease (March 2018). , 90 cases of patients with covid-19 (45 people) and non-covid-19 (45 people) were selected based on the inclusion criteria and the desired parameters were extracted from them. The results were analyzed using SPSS, t-test and Mann-Whitney test.
Results: The statistical analysis of the data of this study did not show any significant difference between mean ejection fraction, heart rate, systolic and diastolic blood pressure in post-heart attack patients with and without covid 19.
Conclusion: Although the statistical analysis of the data of this study did not show a significant difference between the mean ejection fraction, heart rate, systolic and diastolic blood pressure in post-heart attack patients with and without covid-19, due to the emerging nature of the disease, more studies are needed in this area.
- Cardiac ejection fraction; Heart attack; Blood pressure; Heart rate; Covid-19
How to Cite
References
Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877-888.
2. Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test. J Med Virol. 2020;92(10):2004-2010.
3.Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020; 382(24):2372-2374.
4. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-68.
5. Kumar S. Covid-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis. Preprints. 2020, 2020030440.
6.Garg N, McClafferty B, Ramgobin D, Golamari R, Jain R, Jain R. Cardiology and COVID-19: do we have sufficient information? Future Cardiol. 2021;17(4):705-711.
7. Basu-Ray I, Adeboye A, Soos MP. Cardiac manifestations of coronavirus (COVID-19). StatPearls Publishing; 2023.
8. Changal K, Veria S, Mack S, Paternite D, Sheikh SA, Patel M, et al. Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis. BMC Cardiovasc Disord. 2021;21(1):1-10.
9. Alsharif W, Qurashi AJR. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond). 2021;27(2):682-687.
10. Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, et al. Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings. Eur J Heart Fail. 2021;23(11):1891-902.
11.Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323(11):1061-1069.
12. Zwaenepoel B, Dhont S, Hoste E, Gevaert S, Schaubroeck HJFiCM. The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19. Front Cardiovasc Med. 2021;8: 752237.
13. Hamadeh A, Aldujeli A, Briedis K, Tecson KM, Sanz-Sánchez J, Al-Obeidi A, et al. Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction. Am J Cardiol. 2020;131: 1-6.
14. Soulat-Dufour L, Lang S, Ederhy S, Adavane-Scheuble S, Chauvet-Droit M, Nhan P, et al. Left ventricular ejection fraction: an additional risk marker in COVID-19. Arch Cardiovasc Dis. 2020;113(11):760-2.
- Abstract Viewed: 8 times